特発性肺線維症（IPF）の世界市場（2023年版）：薬剤タイプ別（ピルフェニドン、ニンテダニブ、その他）、投与経路別（経口、非経口、その他）、流通経路別、地域別、国別の分析市場インサイトと予測（2019-2029年）

Global Idiopathic Pulmonary Fibrosis (IPF) Market (2023 Edition): Analysis By Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Parenteral, Others), Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

エグゼクティブ・サマリーこの調査レポートは世界の特発性肺線維症市場を薬剤タイプ別（ピルフェニドン、ニンテダニブ、その他）、投与経路別（経口、非経口、その他）、流通チャネル別（病院薬局、小売薬局... もっと見る

出版社	出版年月	電子版価格	納期	ページ数	言語
Azoth Analytics アーゾスアナリティクス	2023年7月1日	US$2,450 シングルユーザライセンスライセンス・価格情報注文方法はこちら	2-3営業日程度	260	英語

サマリー

エグゼクティブ・サマリー

この調査レポートは世界の特発性肺線維症市場を薬剤タイプ別（ピルフェニドン、ニンテダニブ、その他）、投与経路別（経口、非経口、その他）、流通チャネル別（病院薬局、小売薬局、オンラインチャネル）に詳細に分析しています。

調査レポートは、地域（米州、欧州、APAC、中東アフリカ）および11カ国（米国、カナダ、メキシコ、英国、ドイツ、フランス、イタリア、中国、インド、日本、韓国）の詳細な分析をカバーしています。さらに、この調査レポートは、市場規模、年間成長＆潜在能力分析、市場プレイヤーの競争調査、投資機会、需要予測などのデータを提示しています。

また、市場成長指標、阻害要因、需給リスク、その他の重要な統計、市場進化に関連する現在および将来の市場動向の完全な評価についても調査しています。

予測期間2024-2029年において、世界の特発性肺線維症市場はCAGR 46.3%で拡大すると予測されます。特発性肺線維症の世界市場は、2022年の43.9億米ドルから2029年末までに106.4億米ドルを創出すると予測されます。

IPFは生命を脅かす病気であり、進行性で不治の病である。治療によって症状を管理し、病気の進行を抑え、生活の質を改善することができる。ピルフェニドンとニンテダニブは、線維化を遅らせるIPF治療薬として認可されている。重症例では肺移植が必要になることもある。

IPFはまれな疾患と考えられているが、その発症率は時間の経過とともに増加している。世界的には10万人当たり13～20人が罹患していると推定されている。有病率は年齢層が高いほど高く、50歳以上でより頻繁に診断される。IPFは男女ともに罹患するが、男性の方がやや罹患しやすい。現在進行中の研究や臨床試験では、新規の治療法やIPF治療の可能性が検討されている。その中には、抗線維化剤、免疫調節剤、線維化過程に関与する様々な経路を標的とするその他の新規治療アプローチがある。

IPF患者には医学的フォローアップが必要である。間質性肺疾患の専門医と協力して、具体的な治療計画や支援方法を立てる。IPFは、持続的な空咳、息切れ（特に運動時）、疲労感、胸痛を特徴とする。これらの症状は通常、時間の経過とともに発症し、悪化します。

報告書の範囲

- このレポートは特発性肺線維症市場を金額（百万米ドル）別に分析しています。

- 特発性肺線維症市場の過去期間2019-2022年、推定期間2023年、予測期間2024-2029年の分析を紹介します。

- 特発性肺線維症市場を薬剤タイプ別（ピルフェニドン、ニンテダニブ、その他薬剤）に分析しています。

- 特発性肺線維症市場を投与経路別（経口剤、非経口剤、その他ROA）に分析したレポートです。

- 特発性肺線維症市場を流通チャネル別（病院薬局、小売薬局、オンラインチャネル）に分析しています。

- 本レポートの主要な洞察は、SWOTおよびポーターのファイブフォース分析の枠組みを通して提示されています。また、市場の魅力を地域別、サービス別、運営形態別、エンドユーザー別に紹介しています。

- また、業界の主な機会、動向、促進要因、課題についても分析しています。

- 競合の動向、戦略、M&A、新製品開発についても追跡しています。本レポートで分析している企業は、ベーリンガーインゲルハイム、F.ホフマン・ラ・ロシュAG、シプラ社、塩野義製薬、ブリストル・マイヤーズスクイブ社、ユナイテッド・セラピューティクス、ファイブロジェン社、プライアント・セラピューティクス、ガレクト社、CSLベーリング社などです。

ページTOPに戻る

1. Market Background

1.1 Scope and Product Outlook

1.2 Executive Summary

1.3 Research Methodology

2. Strategic Recommendations

2.1 Enhancing R&D operations for the development of novel treatments

2.2 Improving access to treatment

3. Global Idiopathic Pulmonary Fibrosis Market: Historic and Forecast

3.1 Impact Analysis of Macro Economic Factors on Idiopathic Pulmonary Fibrosis Market

3.2 Most bothersome IPF symptom

3.3 Idiopathic Pulmonary Fibrosis diagnosed prevalent cases

3.4 Competitive Landscape for IPF Drugs in Pipeline

3.5 Chronic Cough due to IPF

3.6 Idiopathic Pulmonary Fibrosis: Fact Sheet

3.7 Pathophysiology of Chronic Cough due to IPF

3.8 Comorbidities Associated with Chronic Cough in IPF

3.9 Global Idiopathic Pulmonary Fibrosis Market: Dashboard

3.10 Global Idiopathic Pulmonary Fibrosis Market: Market Value Assessment, 2018-2028 (USD Million)

3.11 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market

3.12 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type

3.12.1 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type Type Overview

3.12.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)

3.12.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)

3.12.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)

3.13 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration

3.13.1 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview

3.13.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

3.13.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)

3.13.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

3.14 Global Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel

3.14.1 Global Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview

3.14.2 Global Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies By Value, 2018H-2028F (USD Million & CAGR)

3.14.3 Global Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

3.14.4 Global Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

4. Global Idiopathic Pulmonary Fibrosis Market, Regional Analysis

4.1 Regional Coverage of the Study

5. Americas Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

5.1 Americas Idiopathic Pulmonary Fibrosis Market: Snapshot

5.2 Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.3 Americas Idiopathic Pulmonary Fibrosis Market: Key Factors

5.4 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type

5.4.1 Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview

5.4.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)

5.4.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)

5.4.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)

5.5 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration

5.5.1 Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview

5.5.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

5.5.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)

5.5.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

5.6 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel

5.6.1 Americas Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview

5.6.2 Americas Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

5.6.3 Americas Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

5.6.4 Americas Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

5.7 Americas Idiopathic Pulmonary Fibrosis Market Segmentation: By Country

5.7.1 United States Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.7.1.1 United States Idiopathic Pulmonary Fibrosis Market, By Drug Type

5.7.1.2 United States Idiopathic Pulmonary Fibrosis Market, By Route of Administration

5.7.1.3 United States Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

5.7.2 Canada Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.7.2.1 Canada Idiopathic Pulmonary Fibrosis Market, By Drug Type

5.7.2.2 Canada Idiopathic Pulmonary Fibrosis Market, By Route of Administration

5.7.2.3 Canada Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

5.7.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

5.7.3.1 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Drug Type

5.7.3.2 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration

5.7.3.3 Rest of Americas Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6. Europe Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

6.1 Europe Idiopathic Pulmonary Fibrosis Market: Snapshot

6.2 Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.3 Europe Idiopathic Pulmonary Fibrosis Market: Key Factors

6.4 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type

6.4.1 Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview

6.4.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)

6.4.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)

6.4.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)

6.5 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration

6.5.1 Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview

6.5.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

6.5.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)

6.5.4 Europe Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

6.6 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel

6.6.1 Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview

6.6.2 Europe Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

6.6.3 Europe Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

6.7 Europe Idiopathic Pulmonary Fibrosis Market Segmentation: By Country

6.7.1 France Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.1.1 France Idiopathic Pulmonary Fibrosis Market, By Drug Type

6.7.1.2 France Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6.7.1.3 France Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

6.7.2 United Kingdom Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.2.1 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Drug Type

6.7.2.2 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6.7.2.3 United Kingdom Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

6.7.3 Italy Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.3.1 Italy Idiopathic Pulmonary Fibrosis Market, By Drug Type

6.7.3.2 Italy Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6.7.3.3 Italy Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

6.7.4 Spain Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.4.1 Spain Idiopathic Pulmonary Fibrosis Market, By Drug Type

6.7.4.2 Spain Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6.7.4.3 Spain Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

6.7.5 Germany Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.5.1 Germany Idiopathic Pulmonary Fibrosis Market, By Drug Type

6.7.5.2 Germany Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6.7.5.3 Germany Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

6.7.6 Rest of Europe Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

6.7.6.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Drug Type

6.7.6.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Route of Administration

6.7.6.3 Rest of Europe Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7. Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

7.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Snapshot

7.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Key Factors

7.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type

7.4.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview

7.4.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)

7.4.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)

7.4.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)

7.5 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration

7.5.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview

7.5.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

7.5.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)

7.5.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

7.6 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel

7.6.1 Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel Overview

7.6.2 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

7.6.3 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

7.6.4 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

7.7 Asia-Pacific Idiopathic Pulmonary Fibrosis Market Segmentation: By Country

7.7.1 China Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.1.1 China Idiopathic Pulmonary Fibrosis Market, By Drug Type

7.7.1.2 China Idiopathic Pulmonary Fibrosis Market, By Route of Administration

7.7.1.3 China Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7.7.2 Japan Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.1.1 Japan Idiopathic Pulmonary Fibrosis Market, By Drug Type

7.7.1.2 Japan Idiopathic Pulmonary Fibrosis Market, By Route of Administration

7.7.1.3 Japan Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7.7.3 South Korea Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.3.1 South Korea Idiopathic Pulmonary Fibrosis Market, By Drug Type

7.7.3.2 South Korea Idiopathic Pulmonary Fibrosis Market, By Route of Administration

7.7.3.3 South Korea Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7.7.4 India Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.4.1 India Idiopathic Pulmonary Fibrosis Market, By Drug Type

7.7.4.2 India Idiopathic Pulmonary Fibrosis Market, By Route of Administration

7.7.4.3 India Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

7.7.5 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

7.7.5.1 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Drug Type

7.7.5.2 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Route of Administration

7.7.5.3 Rest of Asia-Pacific Idiopathic Pulmonary Fibrosis Market, By Distribution Channel

8. Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Historic and Forecast (2018-2028)

8.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Snapshot

8.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Market Size and CAGR, 2018-2028 (USD Million & CAGR)

8.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market: Key Factors

8.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Drug Type

8.4.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Drug Type Overview

8.4.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Pirfenidone, By Value, 2018H-2028F (USD Million & CAGR)

8.4.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Nintedanib, By Value, 2018H-2028F (USD Million & CAGR)

8.4.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other drugs, By Value, 2018H-2028F (USD Million & CAGR)

8.5 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Route of Administration

8.5.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Route of Administration Overview

8.5.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Oral, By Value, 2018H-2028F (USD Million & CAGR)

8.5.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Parenteral, By Value, 2018H-2028F (USD Million & CAGR)

8.5.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Other ROA, By Value, 2018H-2028F (USD Million & CAGR)

8.6 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Segmentation: By Distribution Channel

8.6.1 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market, By Distribution Channel: Overview

8.6.2 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Hospital Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

8.6.3 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Retail Pharmacies, By Value, 2018H-2028F (USD Million & CAGR)

8.6.4 Middle-East & Africa Idiopathic Pulmonary Fibrosis Market Size, By Online Channel, By Value, 2018H-2028F (USD Million & CAGR)

9. Market Dynamics

9.1 Impact Assessment of Market Dynamics on the Global Idiopathic Pulmonary Fibrosis Market

9.2 Drivers

9.3 Restraints

9.4 Trends

10. Industry Ecosystem Analysis

10.1 Macro-Economic Factor Assessment

10.2 Porter’s Five Forces Model

11. Competitive Positioning

11.1 Companies’ Product Positioning

11.2 Market Position Matrix

11.3 Market Share Analysis of Idiopathic Pulmonary Fibrosis Market

11.4 Company Profiles

11.4.1 Boehringer Ingelheim

11.4.2 F. Hoffmann-La Roche AG

11.4.3 Cipla Ltd.

11.4.4 Shionogi & Co., Ltd.

11.4.5 Bristol-Myers Squibb Co.

11.4.6 United Therapeutics

11.4.7 FibroGen, Inc.

11.4.8 Pliant Therapeutics

11.4.9 Galecto Inc.

11.4.10 CSL Behring

ページTOPに戻る

Table of Contents

Summary

Executive Summary

Azoth Analytics has released a research report titled “Idiopathic Pulmonary Fibrosis Market (2023 Edition)” which provides a complete analysis of the global Idiopathic Pulmonary Fibrosis industry in terms of market segmentation by Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Parenteral, Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).

The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 11 countries (United States, Canada, Mexico, United Kingdom, Germany, France, Italy, China, India, Japan, South Korea). Additionally, the research report presents data including market size, yearly growth & potential analysis, the competitive study of market players, investment opportunities and demand forecast.

The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.

During the forecast period, 2024-2029, the Global Idiopathic Pulmonary Fibrosis market is expected to expand at a CAGR of 46.3%. The Global Idiopathic Pulmonary Fibrosis Market is expected to generate USD 10.64 billion by the end of 2029, up from USD 4.39 billion in 2022.

IPF is a life-threatening illness and is both progressive and incurable. Treatments can manage symptoms, limit disease progression, and improve quality of life. Pirfenidone and nintedanib are authorized IPF treatments that slow fibrosis. Severe instances may require lung transplants.

Although IPF is considered a rare disease, its incidence has increased over time. It is estimated that 13 to 20 people per 100,000 are affected globally. The prevalence is higher in older age categories, and the disease is diagnosed more frequently in people over 50. IPF affects both men and women, although men are slightly more susceptible. Ongoing research and clinical trials are investigating novel treatments and potential IPF therapies. Among these are antifibrotic agents, immunomodulatory drugs, and other novel therapeutic approaches that target different pathways implicated in the fibrotic process.

IPF patients need medical follow-ups. Work with interstitial lung disease specialists to create a specific treatment plan and support methods. IPF is characterized by a persistent dry cough, shortness of breath (especially during physical activity), exhaustion, and chest pain. These symptoms typically develop and worsen over time.

Scope of the Report:

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Value (USD Million).

• The report presents the analysis of the Idiopathic Pulmonary Fibrosis Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Drug Type (Pirfenidone, Nintedanib, Other drugs).

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Route of Administration (Oral, Parenteral, Other ROA).

• The report analyses the Idiopathic Pulmonary Fibrosis Market by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Channel).

• The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by services, by mode of operation & by end users.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analyzed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Boehringer Ingelheim, F. Hoffmann-La Roche AG, Cipla Ltd., Shionogi & Co., Ltd., Bristol-Myers Squibb Co., United Therapeutics, FibroGen, Inc., Pliant Therapeutics, Galecto Inc., CSL Behring

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

Azoth Analytics社の健康分野での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

特発性肺線維症（IPF）の世界市場（2023年版）：薬剤タイプ別（ピルフェニドン、ニンテダニブ、その他）、投与経路別（経口、非経口、その他）、流通経路別、地域別、国別の分析市場インサイトと予測（2019-2029年）

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

Azoth Analytics社の健康分野での最新刊レポート

本レポートと同じKEY WORD（drug）の最新刊レポート

よくあるご質問

Azoth Analytics社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?